<DOC>
	<DOCNO>NCT00746837</DOCNO>
	<brief_summary>The purpose study estimate absolute bioavailability steady state 2 dos AZD5672 ( 50 mg 150 mg administer orally daily )</brief_summary>
	<brief_title>AZD5672 Absolute Bioavailability Study</brief_title>
	<detailed_description />
	<mesh_term>N- ( 1- ( 3- ( 3,5-difluorophenyl ) -3- ( 4-methanesulfonylphenyl ) propyl ) piperidin-4-yl ) -N-ethyl-2- ( 4-methanesulfonylphenyl ) acetamide</mesh_term>
	<criteria>Provision inform consent prior study specific procedure . Females childbearing potential Clinically normal physical laboratory finding judge investigator , include negative test result drugofabuse , alcohol cotinine Screening Visit and/or admission ( Day 1 ) study period , negative test result Any clinically significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate Unsuitable venous access intravenous study Participation clinical study involve investigational product within 5 halflives active moiety last dose investigational product 3 month prior first dose ( whichever longer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>AZD5672</keyword>
</DOC>